Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.63)
# 837
Out of 4,953 analysts
96
Total ratings
57.47%
Success rate
4.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PASG Passage Bio | Maintains: Buy | $40 → $10 | $6.93 | +44.40% | 3 | Aug 14, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $97 → $106 | $66.81 | +58.66% | 4 | Aug 7, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $101 → $106 | $57.31 | +84.96% | 4 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $558 → $546 | $390.76 | +39.73% | 8 | Aug 6, 2025 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Buy | $64 | $29.12 | +119.78% | 3 | Jun 20, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $50 | $12.25 | +308.16% | 5 | Jun 18, 2025 | |
| QURE uniQure | Reiterates: Buy | $28 | $15.33 | +82.65% | 6 | May 12, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $55 → $45 | $10.29 | +337.32% | 2 | May 12, 2025 | |
| KRYS Krystal Biotech | Maintains: Buy | $195 → $189 | $144.03 | +31.22% | 4 | May 7, 2025 | |
| BEAM Beam Therapeutics | Maintains: Buy | $78 → $55 | $16.35 | +236.39% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $98 | $20.18 | +385.63% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $64 | $42.48 | +50.66% | 5 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $13.45 | +41.26% | 2 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $17.31 | +61.76% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $6.47 | - | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $3.24 | +455.56% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $12.40 | +37.10% | 2 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.34 | +104.36% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $54.16 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.75 | +300.00% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $3.56 | +517.98% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $24.37 | +23.13% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.05 | +2,661.90% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $458.28 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.84 | +885.92% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $9.51 | +110.30% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $32.10 | +283.18% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $14.11 | +282.71% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $1.11 | +5,305.41% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $36.20 | - | 3 | Jun 26, 2017 |
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $40 → $10
Current: $6.93
Upside: +44.40%
Soleno Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $97 → $106
Current: $66.81
Upside: +58.66%
BioMarin Pharmaceutical
Aug 6, 2025
Maintains: Buy
Price Target: $101 → $106
Current: $57.31
Upside: +84.96%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $558 → $546
Current: $390.76
Upside: +39.73%
Ultragenyx Pharmaceutical
Jun 20, 2025
Reiterates: Buy
Price Target: $64
Current: $29.12
Upside: +119.78%
Dyne Therapeutics
Jun 18, 2025
Reiterates: Buy
Price Target: $50
Current: $12.25
Upside: +308.16%
uniQure
May 12, 2025
Reiterates: Buy
Price Target: $28
Current: $15.33
Upside: +82.65%
Intellia Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $10.29
Upside: +337.32%
Krystal Biotech
May 7, 2025
Maintains: Buy
Price Target: $195 → $189
Current: $144.03
Upside: +31.22%
Beam Therapeutics
May 7, 2025
Maintains: Buy
Price Target: $78 → $55
Current: $16.35
Upside: +236.39%
May 7, 2025
Maintains: Buy
Price Target: $112 → $98
Current: $20.18
Upside: +385.63%
May 1, 2025
Maintains: Buy
Price Target: $65 → $64
Current: $42.48
Upside: +50.66%
Apr 2, 2025
Reiterates: Buy
Price Target: $19
Current: $13.45
Upside: +41.26%
Mar 26, 2025
Reiterates: Buy
Price Target: $28
Current: $17.31
Upside: +61.76%
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $6.47
Upside: -
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $3.24
Upside: +455.56%
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $12.40
Upside: +37.10%
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.34
Upside: +104.36%
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $54.16
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.75
Upside: +300.00%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $3.56
Upside: +517.98%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $24.37
Upside: +23.13%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.05
Upside: +2,661.90%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $458.28
Upside: -
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $2.84
Upside: +885.92%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $9.51
Upside: +110.30%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $32.10
Upside: +283.18%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $14.11
Upside: +282.71%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $1.11
Upside: +5,305.41%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $36.20
Upside: -